AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
22.9 C
New York
Friday, October 16, 2026

Tag: stem cells

newssourceFORcompanycontentinformation1releasesmarket

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo.,...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

If approved, Zemcelpro® is expected to:increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromesbe...

Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the current developmental pipeline for osteoarthritis is robust, with several companies initiating clinical trials to investigate new treatment options or...

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time.

BioRestorative Announces Share Repurchase Program

MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026.

Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its...

Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology

Regenerative Medicine Market to Hit USD 115.6 Billion by 2029 | Rising Demand in Dermatology & Orthopedic Fuels 19.2% CAGR | Valuates Reports

BANGALORE, India, June 16, 2025 /PRNewswire/ -- Regenerative Medicine Market is Segmented by Type (Cell Therapy, Tissue Engineering, Biomaterial), by Application (Dermatology, Cardiovascular, CNS, Orthopedic). The...

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia...

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStem cells

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers